It has been announced, that a novel application of 3D-Bioprinting living tissue models for pharmaceutical testing is being developed at Swansea University-UK. A team of scientists have begun trailing a process, which has been designed to augment the development of new drugs and treatments.
The research team led by Dr. Daniel Thomas of the Welsh Centre for Printing and Coating has produced a process which uses precision deposition technologies to produce complex tissue architectures.
Over the past decade, annual spending on pharmaceutical development has doubled to more than £30 billion per annum. At the same time, in spite of these huge sums invested, the average number of drugs being approved for human use has decreased to one in ten. Currently, pre-clinical studies to test the safety and efficiency of new drugs use laboratory animals and traditional 2D cell culture models. Neither of these methods are completely accurate reflections of how a drug will react in a human.
A solution has emerged in the form of 3D-Bioprinting technology developed for the scalable, accurate and repeatable deposition of biologically active materials. With advances in this bio-manufacturing technology, durable biological tissues for use in testing new pharmaceutical products are now being harnessed and refined. … (read more)